DeepCure Closes $24M Funding Round Led by IAG Capital Partners
Summary
DeepCure, a pioneer in AI-powered small molecule drug discovery, has closed a $24.6 million Series A-1 financing round led by IAG Capital Partners. This brings the total funding raised by DeepCure to over $72 million since its inception.DeepCures innovative platform combines generative AI with physics-based engines to discover novel small-molecule therapies for complex targets. It pinpoints potential interaction sites on proteins and designs synthesizable molecules with optimal properties. Additionally, DeepCure has developed an automated chemistry synthesis platform to enhance the tested molecules speed, quantity, and diversity.DeepCure has achieved technical breakthroughs in AI and chemistry synthesis automation that overcome critical barriers for small molecule discovery, said Dr. Ehsan Jabbarzadeh, Venture Partner at IAG.The Series A-1 proceeds will accelerate DeepCures technology development and advance its immunology and inflammation pipeline toward clinical trials.IAG Capital Partners investment aligns with its commitment to supporting early-stage companies with transformative technologies. These breakthroughs are pivotal to drugging a huge number of intractable targets that are known to have a central role in disease biology, said Alex Kash, Associate at IAG.DeepCures mission is to leverage its AI and automation capabilities to transform drug discovery and bring novel treatments to patients suffering from immunology-related and inflammatory diseases.